A.R.T. Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

A.R.T. Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,502	Closed	-$432K	–	548
2019 Q4	$432K	Buy	+1,502	New	+$326K	0.02%	906
2019 Q3	–	Sell	-6,862	Closed	-$617K	–	1578
2019 Q2	$617K	Buy	6,862 +5,901	+614%	+$474K	0.03%	661
2019 Q1	$84K	Sell	961 -1,960	-67%	-$217K	0.01%	1187
2018 Q4	$411K	Buy	2,921 +596	+26%	+$101K	0.03%	805
2018 Q3	$593K	Sell	2,325 -4,816	-67%	-$1.33M	0.03%	779
2018 Q2	$1.82M	Buy	7,141 +6,153	+623%	+$1.52M	0.07%	395
2018 Q1	$198K	Sell	988 -1,206	-55%	-$240K	0.01%	1268
2017 Q4	$315K	Buy	2,194 +424	+24%	+$68.1K	0.01%	1043
2017 Q3	$291K	Buy	+1,770	New	+$254K	0.01%	1023
2016 Q2	–	Sell	-4,478	Closed	-$599K	–	1497
2016 Q1	$599K	Sell	4,478 -652	-13%	-$72K	0.03%	786
2015 Q4	$1.02M	Sell	5,130 -3,944	-43%	-$854K	0.05%	549
2015 Q3	$1.43M	Buy	+9,074	New	+$2.43M	0.05%	504
2015 Q2	–	Sell	-1,097	Closed	-$503K	–	1588
2015 Q1	$503K	Buy	+1,097	New	+$473K	0.02%	914
2014 Q2	–	Sell	-1,018	Closed	-$471K	–	1424
2014 Q1	$471K	Buy	+1,018	New	+$516K	0.03%	774

Other funds holding KPTI

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

A.R.T. Advisors's KPTI Position: Q1 2020 in Review

A.R.T. Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2020, closing a stake of 1,502 shares — an estimated $432K sold.

A.R.T. Advisors first reported a position in KPTI in Q1 2014 and held it in 14 quarters. The position peaked at $1.82M in Q2 2018. 136 funds tracked by Wall St. Rank hold KPTI as of Q1 2020.

A.R.T. Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 1,502 Karyopharm Therapeutics shares in Q1 2020, an estimated $432K.
A.R.T. Advisors first reported a position in Karyopharm Therapeutics in Q1 2014 and held it in 14 quarters.
A.R.T. Advisors's Karyopharm Therapeutics position peaked at $1.82M in Q2 2018.
136 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.